Platform 03 · Health
A natural, non-antibiotic alternative to antibiotics
Antimicrobial resistance is not bad luck. It is the predictable output of a mechanism: antibiotics apply selective pressure, and bacteria adapt. This platform works by a different mechanism entirely, so it never applies that pressure.
What is proven, and what is not
Three statements that are not the same statement
Clinical validation, applied technology readiness and regulatory authorization get used interchangeably across this industry. They are different things, and conflating them is how credibility is lost. Here is where each application actually stands.
“Ready for deployment” means the technology is developed far enough to transfer to an industrial partner. It does not mean a finished product carries regulatory authorization. Aybar Ecotechnologies develops the technology and its applications; it is not the manufacturer of the finished goods. Finding partners who can take these through manufacturing, registration and commercialization is the purpose of this page.
The mechanism
Why resistance does not develop
Antibiotics interfere with a metabolic pathway. Any mutation that routes around that pathway survives and propagates, which is what makes resistance inevitable rather than unlucky.
This formulation does not compete with bacterial metabolism at all. It dismantles the envelope mechanically.
- The chelating agent strips the divalent cations holding the gram-negative outer membrane together.
- That exposes the peptidoglycan layer normally shielded from enzymatic attack.
- Lysozyme cleaves the peptidoglycan directly, and the cell fails structurally.
- The pH-stabilizing salt keeps the system active under physiological conditions.
Broad-spectrum, including gram-negative
The granted claims cover a composition with bactericidal activity against both gram-positive and gram-negative bacteria. That second one is the boundary most enzyme-based approaches never crossed: lysozyme alone cannot reach the peptidoglycan of a gram-negative cell, because the outer membrane is in the way. The chelation system is what removes that obstacle.
Clinical evidence · dental indication
Measured against the reference antiseptic, in humans
This is not in vitro work, laboratory experimentation, or a theoretical result described in a patent. A comparative clinical study of 70 human subjects, conducted under the corresponding bioethical approvals, set the experimental formulation against chlorhexidine 0.12%, the reference oral antiseptic.
Unpleasant taste was reported by 14% in the extraction group, against 88% for chlorhexidine. Taste perception was unaltered in 0% of experimental cases, against 50% in extraction and 71% in implants.Comparative clinical study · n=70 · patent MX 433331
Favorable results were also reported for pain, inflammation and bleeding control following extractions and implants. Tolerability matters more than it sounds: an antiseptic that patients dislike is an antiseptic patients stop using.
Applications
One platform, four routes to market
Dental and oral care
Chewable tablets, bactericidal gel and irrigation solutions, for antibacterial oral hygiene, gingivitis and periodontal disease, asepsis during dental surgery, and post-extraction and post-implant recovery. This is the validated indication.
Medical and healthcare
Post-surgical asepsis and wound healing, where resistance-free antibacterial action is valuable and the safety profile observed in the dental study is informative, though not a substitute for clinical evaluation in those indications.
Veterinary
Livestock and poultry health, where antibiotic dependency is under regulatory pressure worldwide and a non-antibiotic route has a clear commercial path.
Respiratory and force health protection
Respiratory illness is a persistent operational risk in military settings: close-quarters living, high operational stress, and exposure to airborne hazards including dust, burn pits and industrial emissions. A safe, non-antibiotic platform could contribute to force readiness and lower antibiotic dependency. Establishing that requires the clinical work we are seeking partners to run.
Intellectual property
One family, filed May 2020
Broad-spectrum antibacterial formulations comprising lysozyme and methods of using the same. Inventor of record: Diógenes Aybar-Batista. Patentee: Aybar Ecotechnologies Corp.
- 28 May 2019United States provisional 62/853,215 establishes priority.
- 28 May 2020International filing date. Every member of the family flows from here.
- 17 November 2022Published in the United States as US 2022/0362354 A1.
- 4 November 2025Granted in Japan, patent JP 7768769 (application 2021-571513).
- 23 March 2026Granted in Mexico by IMPI, patent 433331 (solicitud MX/a/2021/014634).
- 28 May 2040Mexican term expires. Twenty years from the international filing date.
| Jurisdiction | Number | Status |
|---|---|---|
| Japan (JPO) | JP 7768769 | Granted |
| Mexico (IMPI) | 433331 | Granted |
| United States | US 2022/0362354 A1 | Pending |
International classification (Mexico): A61K 38/47; A61K 9/00; A61K 47/12; A61K 47/18; A61P 31/00.
A regulatory authorization is not a universal approval of a technology. It attaches to a specific product, its classification, and the jurisdiction where it is made or sold. Any product derived from this platform follows the corresponding pathway in each market a partner chooses to enter.
Partnership
What we are looking for
Partners with the capacity to develop, register, manufacture and commercialize products derived from this technology, through licensing, co-development or other commercial arrangements. Separately, clinical partners for the respiratory work.
Formulation details, know-how and the full technical dossier are shared under a non-disclosure agreement.
Licensing & partnerships
Work with us on what comes next
Aybar Ecotechnologies works through licensing, joint ventures, and equity structures. Request the investor brief for a specific platform, or schedule a technical demonstration with our research team.